The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.

Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.

Pfizer’s abrupt withdrawal of Oxbryta, a drug for sickle cell disease, has sent shockwaves through the medical community.

Significant regulatory news last week included the US Food and Drug Administration (FDA) granting approval for Zevra ...

Gene Therapy: "It is so new ... I wanted to see more success stories before I committed to it," said Davis, who is studying ...

Sonos (SONO – Research Report) received a Hold rating and a $0.00 price target from Craig-Hallum analyst Alex Fuhrman on September 26.

In a report released on September 27, Keith Weiss from Morgan Stanley maintained a Hold rating on Intuit (INTU – Research Report), with a ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Photo shows A bundle of bright backpacks sits on the ground with a child lying down in the middle in front of a group of huddled people ...

Phuket is a province in the south of Thailand. Phuket's beaches face the Andaman Sea allowing the west coast beaches fantastic sunsets right throughout the year. If ...